We are excited to see that One Nucleus Corporate Patron, AstraZeneca, has announced an ambitious goal to achieve $80 billion in annual revenue by 2030, a significant increase from $45 billion in 2023. This growth will be driven by expanding their oncology, biopharmaceuticals and rare disease portfolios and launching 20 new medicines by the end of the decade. Additionally, AstraZeneca plans to sustain growth beyond 2030 by investing in transformative new technologies.
News
Read the latest update on ON Helix 2024 here
The Life Sciences Catalyst Business Lounge, designed to be a regional hotspot for start-ups and world-leading businesses in the life sciences sector, has been opened by Deloitte Cambridge.
The Life Sciences Catalyst Business Lounge is based within Deloitte Cambridge’s existing office and located on the 1st floor.
• Company will host a CEO and key opinion leader webinar at 14.30 BST
• AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI
• Confirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lowering profile irrespective of diabetes type and BMI
New drug discovery platform integrates computational approaches with molecular biology for development of novel degrader therapeutics
Cambridge, UK, 21 May 2024: PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™. The new phenotypic screening platform expands the Company’s capabilities in this emerging therapeutic modality to support the systematic discovery and development of novel molecular glue degraders (MGDs) for targeted protein degradation (TPD).
Arecor Therapeutics plc
(“Arecor” or “the Company”)
AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES
Lehane Consulting Ltd are celebrating our 1 year anniversary! We launched our services in 2023 and have enjoyed a fantastic first year of building our network, sharing our skills and welcoming new customers. To mark our birthday in style, we would like to offer One Nucleus members the opportunity for a 20 minute introductory call - to meet, engage and explore the potential of new projects in 2024.
Drop an email to Lucy@Lehaneconsulting.co.uk quoting #YearOneNucleus
We are delighted to share the results from Aon's 2023 Global Risk Management Survey (GRMS).
The GRMS collects and analyses business leaders' assessment of risk and risk management. The 2023 report is the ninth edition of the survey and the results from both Global and UK respondents reflect the increasingly interconnected nature of risk, with traditional business risks and people risks converging to create significant challenges for organisations.
|
Aon – Life Science Sector Specific Employee Benefits Survey:
Participating in this targeted survey can give you unique data insight to help: